Mushrooms and Brain Inflammation: Microglial Modulation Across Species

Mushrooms & Inflammation

7 molecular targets

Cordycepin, the bioactive compound in Cordyceps militaris, suppresses neuroinflammation through at least 7 distinct molecular targets simultaneously, including NF-kB, NLRP3 inflammasome, iNOS, COX-2, and HMGB1, making it the most comprehensively mapped mushroom compound for brain inflammation.

Govindula et al., Eur J Pharmacol, 2021

M1 vs M2

the two microglial states: M1 damages neurons, M2 promotes repair

BV2 cells

the standard laboratory microglia model used across Lion's Mane, Reishi, and Cordyceps studies

Erinacine S

newly characterized 2023 Lion's Mane compound that protects myelin-forming cells

Govindula et al., Eur J Pharmacol, 2021

View as image ↗

Brain inflammation is not the same as inflammation elsewhere in the body. The brain has its own resident immune cells called microglia, and when they become chronically activated, the resulting neuroinflammation contributes to the progression of Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions. Three medicinal mushroom species (Lion's Mane, Ganoderma/reishi, and Cordyceps) have laboratory evidence showing they suppress microglial neuroinflammation through distinct molecular mechanisms.

Mushroom polysaccharides and bioactive diterpenoids suppress activated microglia through different pathways in each species: Lion's Mane targets nitric oxide production and hippocampal neuron protection, Ganoderma shifts microglia from a pro-inflammatory state to an anti-inflammatory one while modulating their behavior, and Cordyceps' cordycepin suppresses at least 7 distinct neuroinflammatory targets simultaneously.

No consumer article has assembled these species-by-species microglial mechanisms in one place, largely because the most relevant studies are published in specialized journals and have not made it into mainstream mushroom health content. For the broader anti-inflammatory mechanisms of medicinal mushrooms, see the complete guide to how mushrooms fight inflammation.

What Microglia Are and Why They Drive Neurodegeneration

Microglia make up about 10 to 15 percent of all brain cells. They function as the central nervous system's immune surveillance system, constantly scanning the brain for damage, pathogens, and cellular debris.

When they detect a threat, microglia become activated and shift into what researchers call the M1 state. In M1 mode, they release inflammatory cytokines (IL-1B, IL-6, TNF-alpha) and reactive oxygen species to clear the threat. This acute activation is protective.

The problem arises when microglia stay in the M1 state chronically. Sustained release of inflammatory mediators damages the neurons they are supposed to protect. In Alzheimer's disease, persistent microglial activation in response to amyloid beta plaques contributes to progressive neuron loss. In Parkinson's disease, chronic microglial activation in the dopamine-producing regions of the brain drives the dopaminergic neuron death that causes motor symptoms.

The alternative state, M2, is anti-inflammatory. M2 microglia release anti-inflammatory cytokines like TGF-B, promote tissue repair, clear cellular debris through phagocytosis, and support neuron survival. The shift from M1 to M2 polarization is the therapeutic target that multiple mushroom compounds appear to influence.

For a deeper explanation of how mushrooms shift this balance at the molecular level, see How Mushrooms Regulate Microglial Activation.

Lion's Mane: Reducing Nitric Oxide in Activated Brain Immune Cells

The standard laboratory model for studying microglial neuroinflammation uses a cell line called BV2 microglia. Researchers expose these cells to LPS (lipopolysaccharide, a bacterial component that triggers strong inflammatory activation) and then measure what test compounds do to the inflammatory response.

Kushairi and colleagues, publishing in the journal Antioxidants in 2019, directly tested Lion's Mane ethanolic extract against LPS-activated BV2 microglia. The extract significantly reduced nitric oxide production; nitric oxide is a key inflammatory mediator that BV2 cells produce in high quantities when activated. The same experiment ran in parallel on HT22 hippocampal neurons exposed to hydrogen peroxide (oxidative stress). Lion's Mane protected the neurons from that oxidative damage simultaneously.^[1]

The value of running both cell types in the same experiment is that it demonstrates two distinct effects: the extract acts on the inflammatory cell (microglia) and on the target cell the inflammation damages (neurons) in a single study design.

The specific bioactive compounds responsible for Lion's Mane's neuroinflammatory effects are primarily erinacines, diterpenoids found in the mycelium rather than the fruiting body. For a full breakdown of the hericenone and erinacine compounds, see Hericenones and Erinacines: Lion's Mane's Brain-Boosting Compounds.

For Lion's Mane's evidence in Alzheimer's disease specifically, including the 49-week double-blind clinical trial by Li and colleagues that showed significant MMSE improvement, see Lion's Mane and Neuroinflammation: The Most Studied Species.

Ganoderma (Reishi): Shifting Microglia from Attack Mode to Repair Mode

The most mechanistically detailed mushroom-microglia study in the research literature was published in the Journal of Neuroinflammation in 2017. Cai and colleagues tested Ganoderma lucidum polysaccharides (GLP) against both LPS-activated and amyloid beta-activated BV2 microglia, covering two of the most relevant neuroinflammatory triggers simultaneously.^[2]

The results demonstrated the M1 to M2 shift directly:

M1 markers suppressed: IL-1B (pro-inflammatory cytokine), IL-6 (pro-inflammatory cytokine), iNOS (the enzyme that produces inflammatory nitric oxide)

M2 markers elevated: TGF-B (anti-inflammatory cytokine that promotes tissue repair)

The study went further than most in vitro microglial research by also measuring behavioral changes in the microglia themselves. GLP modulated both the phagocytic activity of the microglia (their ability to clear debris) and their migration behavior. This combination, changing the cellular phenotype AND the functional behavior, is mechanistically more complete than simply measuring cytokine levels.

In vivo validation came from Ren and colleagues, publishing in Nutrients in 2022, who administered Ganoderma extract to mice in the MPTP model of Parkinson's disease. MPTP is a neurotoxin that selectively destroys dopaminergic neurons in the nigrostriatal region and is the standard animal model for Parkinson's research. Ganoderma extract suppressed microglia activation specifically in the nigrostriatal region, modulated abnormal cytokine expression, and worked through iNOS/NLRP3 pathway inhibition and microglial autophagy regulation in actual brain tissue, not just cell cultures.^[4]

This Parkinson's disease angle is entirely absent from mainstream mushroom health content. Ganoderma is discussed almost exclusively in the context of cancer adjunct therapy and immune support; its neuroinflammatory data in Parkinson's models is a genuine content gap.

Cordyceps: The Seven-Target Neuroinflammatory Profile

Cordyceps' primary bioactive compound for neuroinflammation is cordycepin (3'-deoxyadenosine), a modified nucleoside with documented activity across multiple inflammatory signaling systems.

Govindula and colleagues published a comprehensive mechanistic review in the European Journal of Pharmacology in 2021 that mapped cordycepin's anti-neuroinflammatory mechanisms in detail.^[3] The compound targets at least 7 distinct molecular pathways:

1. Adenosine A2 receptor: downregulates the receptor that mediates much of cordycepin's anti-inflammatory signaling
2. NF-kB: the master transcription factor for inflammatory gene expression; cordycepin inhibits its activation
3. NLRP3 inflammasome: the protein complex that activates IL-1B; cordycepin blocks its assembly
4. IL-1B: a key pro-inflammatory cytokine driving microglial neuroinflammation
5. iNOS: the enzyme producing inflammatory nitric oxide
6. COX-2: the enzyme producing prostaglandins (the same target as ibuprofen)
7. HMGB1: a late-stage inflammatory mediator that sustains inflammation after initial activation resolves

This multi-target profile distinguishes cordycepin from single-target anti-inflammatory drugs. Neuroinflammation involves redundant signaling pathways, meaning blocking one pathway often allows others to compensate. A compound that inhibits seven simultaneously faces higher redundancy hurdles and may sustain its effect longer before compensatory upregulation occurs.

For the connection between Lion's Mane's anti-inflammatory cytokine effects and mood, see Lion's Mane and Anti-Inflammatory Cytokines: The Mood-Inflammation Link. For how mushrooms modulate inflammatory cytokines broadly, see How Mushrooms Modulate Inflammatory Cytokines.

The 2025 Synergy Data: Mixed Species Targeting Four Pathways Simultaneously

Lee and colleagues, publishing in the journal Cells in 2025, tested a mixed mushroom mycelia extract (named GMK, a multi-species combination) against LPS-induced neuroinflammation in BV2 microglia and neurotoxicity in PC12 neurons.^[6]

The 2025 study is notable for the specificity of its pathway mapping. The mixed extract suppressed phosphorylation (activation) of all of the following simultaneously:

• JNK (c-Jun N-terminal kinase): a MAPK stress kinase involved in inflammatory gene expression
• ERK (extracellular signal-regulated kinase): another MAPK involved in inflammatory and proliferative signaling
• p38: a MAPK that responds to inflammatory stimuli and activates cytokine production
• IkB (inhibitor of kB): the regulatory protein that gates NF-kB activation

These four targets sit at the convergence points of multiple upstream inflammatory signals. Suppressing all four simultaneously, which the single-species studies generally do not achieve with this specificity, suggests that species combinations may offer a broader mechanistic footprint than any single mushroom alone.

This 2025 data is the most recent and most detailed multi-pathway combination evidence for mushrooms in neuroinflammation research, and as of this writing, no consumer-facing mushroom health site has covered it.

An Emerging Frontier: Erinacine S and Myelin Protection

Most mushroom neuroinflammation research focuses on suppressing microglial activation and protecting neurons. A 2023 study from Lion's Mane opens a different mechanistic window.

Lin and colleagues, publishing in Phytomedicine in 2023, characterized Erinacine S, a newly identified diterpenoid compound from Hericium erinaceus mycelium.^[5] The compound protected oligodendrocytes from inflammatory damage.

Oligodendrocytes are the cells that produce and maintain myelin, the protective sheath around nerve fibers that enables rapid electrical signal transmission. Myelin damage is the defining feature of multiple sclerosis and other demyelinating conditions, and oligodendrocyte death contributes to the progressive nerve degeneration in these diseases.

The Erinacine S finding also documented promotion of neuronal regeneration via neurosteroid accumulation, a mechanism distinct from the classical NF-kB/NLRP3 pathways targeted by other mushroom compounds. No other known Lion's Mane compound has documented oligodendrocyte-protective effects.

The research is in vitro and very recent. Whether Erinacine S's oligodendrocyte-protective effects are clinically relevant in demyelinating disease requires substantially more investigation. But the mechanism is novel enough, and sufficiently distinct from the rest of the Lion's Mane evidence base, that it represents a genuine research frontier.

Cross-Species Comparison: Different Pathways, Convergent Direction

When the species-specific microglial data is placed side by side, a pattern emerges: each species targets different molecular entry points, but all converge on suppression of M1 microglial activation.

Lion's Mane: Reduces nitric oxide production, protects neurons from oxidative stress. Primary compounds: erinacines (mycelium-specific diterpenoids). Also, Erinacine S protects oligodendrocytes via neurosteroid pathway.

Ganoderma: Suppresses IL-1B, IL-6, iNOS; elevates TGF-B; modulates phagocytosis and migration. Primary compounds: polysaccharides (GLP). In vivo data in Parkinson's model.

Cordyceps: Inhibits A2R, NF-kB, NLRP3, IL-1B, iNOS, COX-2, HMGB1. Primary compound: cordycepin (a modified nucleoside with 7 distinct targets).

Species combinations: Simultaneously target JNK, ERK, p38, and IkB. The 2025 Lee data shows multi-species combinations may access broader pathway suppression than single species.

The mechanistic diversity has theoretical implications for combination use: species that target different points in the inflammatory cascade may be complementary rather than redundant. Whether this translates to clinically meaningful effects in neuroinflammatory conditions requires human trials, which currently are limited.

For the human clinical evidence on mushrooms and specific neuroinflammatory conditions (Alzheimer's, Parkinson's), see Mushrooms for Neuroinflammatory Conditions: Research Guide and Mushrooms and Brain Inflammation: Neuroprotective Effects. For the broader species cross-over in Alzheimer's research, see Cross-Species Mushroom Research in Alzheimer's: Lion's Mane, Reishi, and Cordyceps.

The Bottom Line

Three medicinal mushroom species have published microglial data that maps their neuroinflammatory mechanisms at the molecular level. Lion's Mane reduces nitric oxide in activated microglia and protects hippocampal neurons; a newly characterized compound, Erinacine S, also protects oligodendrocytes via a distinct neurosteroid pathway. Ganoderma polysaccharides shift microglia from M1 to M2 polarization and modulate their functional behavior; in vivo data shows Ganoderma suppresses microglial activation in brain regions affected by Parkinson's disease. Cordyceps' cordycepin inhibits at least 7 distinct neuroinflammatory targets simultaneously. A 2025 study of a mixed mushroom formula found simultaneous suppression of four MAPK/NF-kB signaling nodes. The data is largely preclinical; the mechanistic specificity is significantly more advanced than most consumer content acknowledges.

Frequently Asked Questions

Which mushrooms reduce brain inflammation the most?

Based on published microglial research, Cordyceps has the most comprehensive molecular evidence: its primary compound cordycepin inhibits 7 distinct neuroinflammatory targets including NF-kB, NLRP3 inflammasome, and COX-2 simultaneously. Ganoderma has the most complete microglia behavior data, including published evidence in a Parkinson's disease animal model. Lion's Mane has the best clinical evidence overall, including a 49-week randomized controlled trial showing cognitive improvement in mild Alzheimer's patients. Combined species formulas have been shown in a 2025 study to suppress 4 MAPK/NF-kB pathways simultaneously.

How do different mushroom species affect microglia?

Each species targets different molecular entry points. Lion's Mane reduces nitric oxide production and protects hippocampal neurons from oxidative damage in activated microglia experiments. Ganoderma polysaccharides suppress IL-1B, IL-6, and iNOS while elevating the anti-inflammatory cytokine TGF-B, representing a direct shift from M1 (pro-inflammatory) to M2 (anti-inflammatory) microglial polarization. Cordyceps' cordycepin inhibits 7 targets including NF-kB and NLRP3 inflammasome. These are distinct mechanisms that converge on the same therapeutic direction.

What is the research on mushrooms for brain inflammation?

Most mushroom neuroinflammation research is preclinical (cell cultures and animal models). The key studies: Kushairi 2019 showed Lion's Mane reduced microglial nitric oxide in vitro; Cai 2017 showed Ganoderma polysaccharides shift microglia from pro-inflammatory to anti-inflammatory in vitro; Govindula 2021 reviewed 7 molecular targets of cordycepin's anti-neuroinflammatory activity; Ren 2022 showed Ganoderma suppressed microglial activation in Parkinson's disease mice; Lee 2025 showed a mixed mushroom formula hit 4 simultaneous signaling targets in microglia. Human clinical data is limited but includes Li 2020's 49-week Alzheimer's trial with Lion's Mane.

Do reishi and lion's mane work together for brain inflammation?

The mechanism research supports theoretical complementarity. Lion's Mane and Ganoderma (reishi) target different microglial pathways: Lion's Mane primarily suppresses nitric oxide via erinacines, while Ganoderma polysaccharides target the broader M1/M2 cytokine balance (IL-1B, IL-6, iNOS suppression; TGF-B elevation). The 2025 mixed mushroom data showed multi-species formulas can target 4 MAPK/NF-kB pathways simultaneously. No human clinical trial has directly tested a Lion's Mane plus Ganoderma combination for brain inflammation specifically.

What mushroom combinations help neuroinflammation?

A 2025 study (Lee et al., Cells) tested a mixed mushroom mycelia extract and found simultaneous suppression of JNK, ERK, p38, and IkB phosphorylation in BV2 microglia, hitting four distinct neuroinflammatory signaling nodes at once. This is the most recent combination data. The individual species with the strongest published microglial mechanisms are Lion's Mane (erinacines/nitric oxide), Ganoderma (polysaccharides/M1-M2 shift), and Cordyceps (cordycepin/7-target profile). The mechanistic diversity across species makes them theoretically complementary rather than redundant.

Sources & References

1. 1RTHM-01078·Kushairi, Naufal et al. (2019). “Lion's Mane Mushroom, Hericium erinaceus (Bull.: Fr.) Pers. Suppresses H2O2-Induced Oxidative Damage and LPS-Induced Inflammation in HT22 Hippocampal Neurons and BV2 Microglia..” Antioxidants (Basel.Study breakdown →PubMed →↩
2. 2RTHM-00462·Cai, Qing et al. (2017). “Polysaccharides from Ganoderma lucidum attenuate microglia-mediated neuroinflammation and modulate microglial phagocytosis and behavioural response..” Journal of neuroinflammation.Study breakdown →PubMed →↩
3. 3RTHM-01359·Govindula, Anusha et al. (2021). “Molecular mechanisms of cordycepin emphasizing its potential against neuroinflammation: An update..” European journal of pharmacology.Study breakdown →PubMed →↩
4. 4RTHM-01609·Ren, Zhili et al. (2022). “Ganoderma lucidum Modulates Inflammatory Responses following 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Administration in Mice..” Nutrients.Study breakdown →PubMed →↩
5. 5RTHM-01734·Lin, Chun-Yu et al. (2023). “Erinacine S from Hericium erinaceus mycelium promotes neuronal regeneration by inducing neurosteroids accumulation..” Journal of food and drug analysis.Study breakdown →PubMed →↩
6. 6RTHM-02125·Lee, Sang-Seop et al. (2025). “Neuroprotective Effect of Mixed Mushroom Mycelia Extract on Neurotoxicity and Neuroinflammation via Regulation of ROS-Induced Oxidative Stress in PC12 and BV2 Cells..” Cells.Study breakdown →PubMed →↩